Medicare Enrolled
Dr. Scott Tetreault, M.D.
Medical Oncology · Tallahassee, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Tetreault from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Tetreault? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Tetreault
Dr. Scott Tetreault is a medical oncology in Tallahassee, FL, with 20 years in practice. Based on federal Medicare data, Dr. Tetreault performed 75,107 Medicare services across 1,758 unique beneficiaries.
Between the years covered by Open Payments, Dr. Tetreault received a total of $16,024 from 94 pharmaceutical and/or device companies across 946 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Tetreault is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 30% volume in FL$ $16,024 industry payments
Medicare Practice Summary
Medicare Utilization ↗75,107
Medicare services
Top 30% in FL for medical oncology
1,758
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~3,755 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 19,400 | $0 | $5 |
| Iron infusion (Feraheme) | 14,280 | $0 | $4 |
| Pembrolizumab injection (Keytruda) | 11,000 | $43 | $137 |
| Epoetin alfa injection (Procrit) for anemia | 8,221 | $6 | $23 |
| Anti-nausea injection (aprepitant) | 7,150 | $1 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,660 | $19 | $51 |
| Dexamethasone injection (steroid) | 2,964 | $0 | $3 |
| Iron infusion (Monoferric) | 2,000 | $17 | $57 |
| Complete blood count (CBC) with differential | 1,232 | $8 | $29 |
| Blood draw (venipuncture) | 1,031 | $8 | $9 |
| Anti-nausea injection (Aloxi/palonosetron) | 740 | $1 | $28 |
| Anti-nausea injection (ondansetron/Zofran) | 512 | $0 | $9 |
| Drug injection, under skin or into muscle | 350 | $10 | $69 |
| Administration of chemotherapy into vein, 1 hour or less | 349 | $97 | $378 |
| Injection of additional new drug or substance into vein | 309 | $12 | $61 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 264 | $21 | $84 |
| Office visit, established patient (30-39 min) | 242 | $94 | $339 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 218 | $47 | $189 |
| Office visit, established patient (20-29 min) | 204 | $63 | $239 |
| Injection, diphenhydramine hcl, up to 50 mg | 162 | $1 | $3 |
| Red blood count, automated test | 125 | $4 | $10 |
| Administration of chemotherapy into vein, each additional hour | 94 | $22 | $79 |
| Administration of additional new drug or substance into vein, 1 hour or less | 83 | $49 | $178 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 76 | $23 | $89 |
| Office visit, established patient, complex (40-54 min) | 70 | $136 | $474 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 67 | $3 | $11 |
| Injection of drug or substance into vein | 55 | $28 | $156 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 45 | $18 | $59 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 43 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 28 | $15 | $56 |
| New patient office visit, complex (60-74 min) | 24 | $172 | $585 |
| Automated urinalysis | 23 | $2 | $8 |
| New patient office visit (45-59 min) | 23 | $115 | $453 |
| Infusion into a vein for hydration, each additional hour | 17 | $10 | $42 |
| Infusion, normal saline solution , 1000 cc | 17 | $2 | $7 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 15 | $1 | $7 |
| Initial hospital admission, high complexity | 14 | $137 | $556 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
22.4% high complexity
73.4% medium
4.1% routine
Industry Payment Transparency
Open Payments through 2024 ↗$16,024
Total received (2018-2024)
Avg $2,289/year across 7 years
Top 32% in FL for medical oncology
94
Companies
946
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$15,828 (98.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$197 (1.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,998
2023$2,269
2022$2,460
2021$2,490
2020$1,969
2019$2,458
2018$2,380
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$1,738
Amgen Inc.
$1,208
Celgene Corporation
$1,022
AstraZeneca Pharmaceuticals LP
$982
Novartis Pharmaceuticals Corporation
$630
GENZYME CORPORATION
$548
Genentech USA, Inc.
$526
Merck Sharp & Dohme Corporation
$524
Ipsen Biopharmaceuticals, Inc
$508
Merck Sharp & Dohme LLC
$498
Daiichi Sankyo Inc.
$417
Seagen Inc.
$395
Gilead Sciences, Inc.
$361
PFIZER INC.
$357
Lilly USA, LLC
$343
GlaxoSmithKline, LLC.
$310
Eisai Inc.
$309
Astellas Pharma US Inc
$296
Janssen Biotech, Inc.
$283
Takeda Pharmaceuticals U.S.A., Inc.
$250
Regeneron Healthcare Solutions, Inc.
$207
Octapharma USA, Inc.
$204
Alexion Pharmaceuticals, Inc.
$203
Incyte Corporation
$203
Bayer HealthCare Pharmaceuticals Inc.
$201
Exelixis Inc.
$176
Boehringer Ingelheim Pharmaceuticals, Inc.
$166
TESARO, Inc.
$145
JAZZ PHARMACEUTICALS INC.
$143
AbbVie Inc.
$132
Seattle Genetics, Inc.
$124
Foundation Medicine, Inc.
$117
ABBVIE INC.
$111
SANOFI-AVENTIS U.S. LLC
$98
Taiho Oncology, Inc.
$94
Lexicon Pharmaceuticals, Inc.
$93
Agios Pharmaceuticals, Inc.
$92
ARRAY BIOPHARMA INC
$82
AMAG Pharmaceuticals, Inc.
$80
Stemline Therapeutics Inc.
$78
TerSera Therapeutics LLC
$78
Pharmacosmos Therapeutics Inc.
$64
EMD Serono, Inc.
$60
Rigel Pharmaceuticals, Inc.
$58
TAIHO ONCOLOGY, INC.
$57
Karyopharm Therapeutics Inc.
$56
G1 Therapeutics, Inc.
$55
CSL Behring
$55
MorphoSys, US Inc.
$54
Emmaus Medical, Inc.
$52
BeiGene USA, Inc.
$49
Sysmex Inostics Inc
$45
INSYS Therapeutics Inc
$45
PUMA BIOTECHNOLOGY, INC.
$43
EISAI INC.
$40
Bayer Healthcare Pharmaceuticals Inc.
$40
Pharmacyclics LLC, an AbbVie Company
$39
Heron Therapeutics, Inc.
$37
ADC Therapeutics America, Inc.
$34
Kyowa Kirin, Inc.
$34
Jazz Pharmaceuticals Inc.
$33
SOBI, INC
$33
Aveo Pharmaceuticals, Inc.
$32
Alnylam Pharmaceuticals Inc.
$31
Dendreon Pharmaceuticals LLC
$30
MEDIVATION FIELD SOLUTIONS LLC
$30
Genmab U.S., Inc.
$30
Dova Pharmaceuticals
$29
SERVIER PHARMACEUTICALS LLC
$29
Coherus Biosciences Inc.
$29
Blueprint Medicines Corporation
$29
Kite Pharma, Inc.
$28
Novocure Inc.
$28
Global Blood Therapeutics, Inc.
$28
Mirati Therapeutics, Inc.
$28
Myovant Sciences Inc.
$26
Acrotech Biopharma LLC
$25
Janssen Pharmaceuticals, Inc
$25
Clovis Oncology, Inc.
$22
Array BioPharma Inc.
$21
ImmunoGen, Inc.
$20
CTI BioPharma Corp.
$18
Pharmacyclics LLC, An AbbVie Company
$18
TG THERAPEUTICS, INC.
$17
Horizon Therapeutics plc
$17
TOLMAR Pharmaceuticals, Inc.
$15
Apellis Pharmaceuticals, Inc.
$14
AbbVie, Inc.
$14
Puma Biotechnology, Inc.
$14
Verastem, Inc.
$14
Servier Pharmaceuticals LLC
$13
SUN PHARMACEUTICAL INDUSTRIES INC.
$12
TG Therapeutics, Inc.
$12
Sirtex Medical Inc
$7
Top 3 companies account for 24.8% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALUNBRIG · AYVAKIT · Afstyla · Alecensa · Aliqopa · Avastin · BELEODAQ · BLENREP · BOSULIF · BRAFTOVI · BRUKINSA · Blincyto · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Cinvanti · Cometriq · Copiktra · DARZALEX · Doptelet · ELAHERE · ELIGARD · ELIQUIS · ELITEK · ELZONRIS · EMPLICITI · ENHERTU · ERLEADA · EVENITY · Elahere · Endari · Enhertu · Epkinly · FARESTON · FERAHEME · FOTIVDA · FOUNDATIONONE · Fabhalta · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · HYQVIA · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · IMJUDO · INJECTAFER · INLYTA · INQOVI · INREBIC · Idelvion · Inrebic · JAKAFI · JEVTANA · Jivi · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kyprolis · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lupron Depot · MEKINIST · MONJUVI · MONOFERRIC · MVASI · NERLYNX · NINLARO · Nerlynx · Neulasta · Nplate · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OJJAARA · ONUREG · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Onivyde · Optune · Orserdu · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROVENGE · PYRUKYND · Padcev · Perjeta · Polivy · Pomalyst · Poteligeo · Prolia · REBLOZYL · RETEVMO · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN LAR · SARCLISA · SCEMBLIX · SHINGRIX · SIR-Spheres Microspheres · SOLIRIS · SOMATULINE DEPOT · SPRYCEL · SUBSYS · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · Tavalisse · Tecentriq · Tibsovo · Trodelvy · UKONIQ · ULTOMIRIS · Udenyca · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VYXEOS · Venclexta · Vitrakvi · Vonjo · XALKORI · XARELTO · XPOVIO · XTANDI · Xermelo · Xofigo · Xtandi · YONSA · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $21 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
5
Per 100K population
1.7
County median income
$65,074
Nearest hospital
TALLAHASSEE MEMORIAL HEALTHCARE
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Tetreault is a mixed practice specialist, with above-average Medicare volume (top 30% in FL), and low-engagement industry engagement, with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Tetreault experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Tetreault performed 19,400 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Tetreault receive payments from pharmaceutical companies?
Yes. Dr. Tetreault received a total of $16,024 from 94 companies across 946 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Tetreault's costs compare to other medical oncologys in Tallahassee?
Dr. Tetreault's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Tetreault) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Tallahassee
Browse medical oncologys in Tallahassee ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Amgen Inc. Payments to Doctors
See all physicians who received payments from Amgen Inc..
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology